keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/28916345/is-a-technetium-99m-macroaggregated-albumin-scan-essential-in-the-workup-for-selective-internal-radiation-therapy-with-yttrium-90-an-analysis-of-532-patients
#1
Lidia Sancho, Macarena Rodriguez-Fraile, Jose Ignacio Bilbao, Carmen Beorlegui Arteta, Mercedes Iñarrairaegui, Veronica Moran, Bruno Sangro
PURPOSE: To determine if baseline patient, tumor, and pretreatment evaluation characteristics could help identify patients who require technetium-99m ((99m)Tc) macroaggregated albumin ((99m)Tc MAA) imaging before selective internal radiation therapy (SIRT). MATERIALS AND METHODS: In this retrospective analysis, 532 consecutive patients with primary (n = 248) or metastatic (n = 284) liver tumors were evaluated between 2006 and 2015. Variables were compared between patients in whom (99m)Tc MAA imaging results contraindicated/modified SIRT administration with yttrium-90 ((90)Y) resin microspheres and those who were treated as initially planned...
September 13, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28902765/low-dose-90y-pet-ct-imaging-optimized-for-lesion-detectability-and-quantitative-accuracy-a-phantom-study-to-assess-the-feasibility-of-pretherapy-imaging-to-plan-the-therapeutic-dose
#2
Maryam Khazaee, Alireza Kamali-Asl, Parham Geramifar, Arman Rahmim
OBJECTIVE: The overall aim of this work is to optimize the reconstruction parameters for low-dose yttrium-90 (Y) PET/computed tomography (CT) imaging, and to determine Y minimum detectable activity, in an endeavor to investigate the feasibility of performing low-dose Y imaging in-vivo to plan the therapeutic dose in radioembolization. MATERIALS AND METHODS: This study was carried out using a Siemens Biograph 6 True Point PET/CT scanner. A Jaszczak phantom containing five hot syringes was imaged serially over 15 days...
September 11, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28900709/pretransplant-intra-arterial-liver-directed-therapy-does-not-increase-the-risk-of-hepatic-arterial-complications-in-liver-transplantation-a-single-center-10-year-experience
#3
Joseph R Kallini, Ahmed Gabr, Rehan Ali, Nadine Abouchaleh, Ahsun Riaz, Talia Baker, Laura Kulik, Juan Caicedo, Riad Salem, Robert J Lewandowski
PURPOSE: To investigate the association between pretransplant intra-arterial liver-directed therapy (IAT) for hepatocellular carcinoma (HCC) and hepatic arterial complications (HAC) in orthotopic liver transplantation (OLT) [namely hepatic artery thrombosis (HAT) and/or the need for hepatic arterial conduit]. METHODS: A total of 175 HCC patients (mean age: 60 years) underwent IAT with either transarterial chemoembolization or yttrium-90 (90Y) transarterial radioembolization prior to OLT between 2003 and 2013...
September 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#4
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28890809/a-single-institute-retrospective-trial-of-concurrent-chemotherapy-with-sir-spheres-%C3%A2-versus-sir-spheres-%C3%A2-alone-in-chemotherapy-resistant-colorectal-cancer-liver-metastases
#5
May Cho, Jonathan Kessler, John J Park, Aram Lee, Jun Gong, Gagandeep Singh, Yi-Jen Chen, Philip H G Ituarte, Marwan Fakih
BACKGROUND: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIR-Spheres(®)) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres(®) with concurrent chemotherapy vs. SIR-Spheres(®) alone on liver PFS in patients with colorectal liver metastases (CRLM)...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28888827/tumor-dose-response-in-yttrium-90-resin-microsphere-embolization-for-neuroendocrine-liver-metastases-a-tumor-specific-analysis-with-dose-estimation-using-spect-ct
#6
Orapin Chansanti, Younes Jahangiri, Yusuke Matsui, Akira Adachi, Yindee Geeratikun, John A Kaufman, Kenneth J Kolbeck, Jeffrey S Stevens, Khashayar Farsad
PURPOSE: To evaluate dose-response relationship in yttrium-90 ((90)Y) resin microsphere radioembolization for neuroendocrine tumor (NET) liver metastases using a tumor-specific dose estimation based on technetium-99m-labeled macroaggregated albumin ((99m)Tc MAA) single photon emission computed tomography (SPECT)-CT. MATERIALS AND METHODS: Fifty-five tumors (mean size 3.9 cm) in 15 patients (10 women; mean age 57 y) were evaluated. Tumor-specific absorbed dose was estimated using a partition model...
September 6, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28881497/therapies-for-advanced-stage-hepatocellular-carcinoma-with-macrovascular-invasion-or-metastatic-disease-a-systematic-review-and-meta-analysis
#7
REVIEW
Richard S Finn, Andrew X Zhu, Farah Wigdan, Jehad Almasri, Feras Zaiem, Larry J Prokop, Mohammad Hassan Murad, Khaled Mohammed
Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors such as macrovascular invasion and extrahepatic spread. We aimed to synthesize the evidence for the treatment of patients with advanced HCC based on these baseline characteristics including patients with both Child-Pugh scores of A and B...
September 7, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28879621/survival-analysis-of-advanced-hcc-treated-with-radioembolization-comparing-impact-of-clinical-performance-status-versus-vascular-invasion-metastases
#8
Rehan Ali, Ahmed Gabr, Nadine Abouchaleh, Ali Al Asadi, Ronald A Mora, Laura Kulik, Michael Abecassis, Ahsun Riaz, Riad Salem, Robert J Lewandowski
PURPOSE: In this study, we aim to compare the effects of prognostic indicators on survival analysis for Barcelona Clinic Liver Cancer (BCLC) C patients undergoing yttrium-90 radioembolization (Y-90). METHODS: A prospectively acquired database (2003-2017) for BCLC C hepatocellular carcinoma (HCC) patients that underwent radioembolization with Y-90 was searched. The criteria for BCLC C status (Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or 2, metastases, and/or portal vein thrombosis (PVT)) were recorded...
September 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28875374/yttrium-90-radioembolization-treatment-for-unresectable-hepatocellular-carcinoma-a-single-centre-prognostic-factors-analysis
#9
C Floridi, F Pesapane, S A Angileri, D De Palma, F Fontana, F Caspani, A Barile, A Del Sole, C Masciocchi, G Lucignani, G Carrafiello
The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method...
September 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28869617/a-phase-1-trial-of-90-y-zevalin-radioimmunotherapy-with-autologous-stem-cell-transplant-for-multiple-myeloma
#10
A Dispenzieri, A D'Souza, M A Gertz, K Laumann, G Wiseman, M Q Lacy, B LaPlant, F Buadi, S R Hayman, S K Kumar, D Dingli, W J Hogan, S M Ansell, D A Gastineau, D J Inwards, I N Micallef, L F Porrata, P B Johnston, M R Litzow, T E Witzig
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan ((90)Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). In a 3+3 trial design, 30 patients received rituximab 250 mg/m(2) with indium-111 ibritumomab tiuxetan ((111)In-Zevalin) for dosimetry (day -22); rituximab 250 mg/m(2) with escalating doses of (90)Y-Zevalin (day -14); melphalan 100 mg/m(2) (days -2,-1) followed by ASCT (day 0) and sargramostim (GM-CSF, day 0) until neutrophil engraftment...
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28868022/successful-yttrium-90-microsphere-radioembolization-for-hepatic-metastases-of-prostate-cancer
#11
Alexander C Bunck, Daniel Pinto Dos Santos, De-Hua Chang, Marcel Reiser, David Pfister, Anne Bunck, Alexander Drzezga, David Maintz, Matthias Schmidt
Prostate cancer is the most common solid tumor malignancy worldwide with an estimated 180,000 new cases of prostate cancer and 26,000 deaths in the USA in 2016. Although significant advances in the treatment of prostate cancer have recently been made, the treatment of metastatic disease remains a challenge. With visceral metastases marking more advanced tumor stages, liver involvement is associated with the worst prognosis. So far, no locoregional treatment regimens for the management of liver metastases of prostatic cancer exist...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28859566/history-of-psychosurgery-at-sainte-anne-hospital-paris-france-through-translational-interactions-between-psychiatrists-and-neurosurgeons
#12
Marc Zanello, Johan Pallud, Nicolas Baup, Sophie Peeters, Baris Turak, Marie Odile Krebs, Catherine Oppenheim, Raphael Gaillard, Bertrand Devaux
Sainte-Anne Hospital is the largest psychiatric hospital in Paris. Its long and fascinating history began in the 18th century. In 1952, it was at Sainte-Anne Hospital that Jean Delay and Pierre Deniker used the first neuroleptic, chlorpromazine, to cure psychiatric patients, putting an end to the expansion of psychosurgery. The Department of Neuro-psychosurgery was created in 1941. The works of successive heads of the Neurosurgery Department at Sainte-Anne Hospital summarized the history of psychosurgery in France...
September 2017: Neurosurgical Focus
https://www.readbyqxmd.com/read/28852599/impressive-response-to-concomitant-platinum-based-chemotherapy-and-yttrium-90-in-a-patient-with-heavily-pretreated-triple-negative-breast-cancer-widely-metastasized-to-the-liver
#13
Aurelio Castrellon, Steven M Nguyen, Federico Bengoa, Ana Botero, Luis E Raez
Metastatic triple-negative breast cancer (TNBC) constitutes a heterogeneous group of diseases with systemic treatment options limited to cytotoxic chemotherapy at the time being. The disease tends to affect visceral organs more frequently when compared to hormone receptor-positive breast cancer. The prognoses of patients with heavily pretreated disease affecting the liver are very dismal. We present the response to radioembolization and systemic chemotherapy in a seriously ill patient who had undergone previous lines of chemotherapy for TNBC with extensive liver metastases...
June 28, 2017: Curēus
https://www.readbyqxmd.com/read/28839518/extrahepatic-metastasis-of-hepatocellular-carcinoma-to-the-paravertebral-muscle-a-case-report
#14
Kazuhiro Takahashi, Krishna G Putchakayala, Mohamed Safwan, Dean Y Kim
Identification of extrahepatic metastases (EHM) of hepatocellular carcinoma (HCC) has been paradoxically increasing due to an increase in the survival of HCC patients. However, metastasis of HCC to the skeletal muscle tissue is extremely rare. We describe a unique case of HCC metastasizing to the paravertebral muscle. A 55-year-old man with a history of hepatitis B cirrhosis underwent partial liver resection with complete removal of HCC. Three months later, a computed tomography (CT) scan showed intrahepatic recurrence...
August 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28837044/estimation-of-lung-shunt-fraction-from-simultaneous-fluoroscopic-and-nuclear-images
#15
Sandra van der Velden, Remco Bastiaannet, Arthur J A T Braat, Marnix G E H Lam, Max A Viergever, Hugo W A M de Jong
Radioembolisation with yttrium-90 (<sup>90</sup>Y) is increasingly used as a treatment of unresectable liver malignancies. For safety, a scout dose of technetium-99m macroaggregated albumin (<sup>99m</sup>Tc-MAA) is used prior to the delivery of the therapeutic activity to mimic the deposition of <sup>90</sup>Y. One-day procedures are currently limited by the lack of nuclear images in the intervention room. To cope with this limitation, an interventional simultaneous fluoroscopic and nuclear imaging device is currently being developed...
August 24, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28812136/clinical-outcomes-of-y90-radioembolization-for-recurrent-hepatocellular-carcinoma-following-curative-resection
#16
Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur, Laura Kulik, Robert J Lewandowski, Riad Salem
PURPOSE: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. METHODS: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#17
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
September 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28767473/acquired-hemophilia-a-after-hepatic-yttrium-90-radioembolization-a-case-report
#18
Susanna Tribuzi, Alessia Naccarato, Lorella Pelagalli, Marco Covotta, Giulia Torregiani, Claudia Claroni, Ester Forastiere
Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII. We report a case of a 65-year-old man with hepatocellular carcinoma who bled massively after a hepatic Yttrium-90 radioembolization procedure (Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres [SIRTex]). An acquired deficiency of factor VIII was diagnosed and successfully treated with recombinant activated factor VII and immunosuppression...
August 1, 2017: A & A Case Reports
https://www.readbyqxmd.com/read/28758319/treatment-options-for-unresectable-hcc-with-a-focus-on-sirt-with-yttrium-90-resin-microspheres
#19
REVIEW
Eric A Wang, Jeff P Stein, Ross J Bellavia, Scott R Broadwell
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC...
July 30, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28740906/the-development-commercialization-and-clinical-context-of-yttrium-90-radiolabeled-resin-and-glass-microspheres
#20
REVIEW
Mark A Westcott, Douglas M Coldwell, David M Liu, Joseph F Zikria
Selective internal radiation therapy has emerged as a well-accepted therapeutic for primary and metastatic hepatic malignancies. This therapeutic modality requires the combined efforts of multiple medical disciplines to ensure the safe delivery of yttrium-90 ((90)Y)-labeled microspheres. The development of this therapy followed decades of clinical research involving tumor vascularity and microsphere development. Today, it is essential that treating physicians have a thorough understanding of hepatic tumor vascularity and (90)Y microsphere characteristics before undertaking this complex intervention...
October 2016: Advances in Radiation Oncology
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"